GTC
HRTX icon

Ghost Tree Capital’s Heron Therapeutics HRTX Stock Holding History

Ghost Tree Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,000
Closed -$2.44M – 61
2015
Q3 		$2.44M Buy
+100,000
New +$3.33M 1.1% 38

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ghost Tree Capital's HRTX Position: Q3 2016 in Review

Ghost Tree Capital sold out of Heron Therapeutics (HRTX) in Q3 2016, closing a stake of 25,000 shares — an estimated $451K sold.

Ghost Tree Capital first reported a position in HRTX in Q2 2014 and held it in 4 quarters. The position peaked at $862K in Q2 2014. 91 funds tracked by Wall St. Rank hold HRTX as of Q3 2016.

  • Ghost Tree Capital reported no remaining Heron Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Ghost Tree Capital sold 25,000 Heron Therapeutics shares in Q3 2016, an estimated $451K.
  • Ghost Tree Capital first reported a position in Heron Therapeutics in Q2 2014 and held it in 4 quarters.
  • Ghost Tree Capital's Heron Therapeutics position peaked at $862K in Q2 2014.
  • 91 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2016.

Based on Ghost Tree Capital's 13F filing for Q3 2016, filed 14 Nov 2016.